Showing results (161-170 of 634) with videos related to

Sort By:
Pageof 64
Plos One|September 12, 2013
Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?Inga Karch, Elisa Schipper, Henriette Christgen, et al.
The Journal of Molecular Diagnostics : JMD|July 21, 2017
Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation DetectionStephan Bartels, Sascha Persing, Britta Hasemeier, et al.
Frontiers in Oncology|May 7, 2021
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung CancerMei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, et al.
Surgery Today|August 27, 2013
DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective studyCarsten Kamphues, Nadine Al-Abadi, Angelika Dürr, et al.
Diagnostic Pathology|March 1, 2013
CognitionMaster: an object-based image analysis frameworkStephan Wienert, Daniel Heim, Manato Kotani, et al.
BMC Cancer|June 29, 2021
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trialPetros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, et al.
International Journal of Cancer|October 24, 2018
Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomasSteffen Dietz, Aviezer Lifshitz, Daniel Kazdal, et al.
European Radiology|July 2, 2024
Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomogramsAdrian Schrader, Nils Netzer, Thomas Hielscher, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centersIoannis Zerdes, Caroline Kamali, Berglind Johannsdottir, et al.
Oncotarget|June 21, 2016
Molecular driver alterations and their clinical relevance in cancer of unknown primary siteHarald Löffler, Nicole Pfarr, Mark Kriegsmann, et al.
Pageof 64